Zobrazeno 1 - 10
of 138
pro vyhledávání: '"Arthur R. Thompson"'
Autor:
Ruth A. Ettinger, Joseph A. Liberman, Devi Gunasekera, Komal Puranik, Eddie A. James, Arthur R. Thompson, Kathleen P. Pratt
Publikováno v:
Blood Advances, Vol 2, Iss 4, Pp 309-322 (2018)
Abstract: Factor VIII (FVIII)–neutralizing antibodies (inhibitors) are a serious complication in hemophilia A (HA). The peptide FVIII2194-2213 contains an immunodominant HLA-DRA*01-DRB1*01:01 (DRB1*01:01)-restricted epitope recognized by CD4+ T-eff
Externí odkaz:
https://doaj.org/article/8cdfc0df3f83466e80e9f6064c811ebe
Autor:
Jasper C Lin, Ruth A Ettinger, Jason T Schuman, Ai-Hong Zhang, Muhammad Wamiq-Adhami, Phuong-Cac T Nguyen, Shelley M Nakaya-Fletcher, Komal Puranik, Arthur R Thompson, Kathleen P Pratt
Publikováno v:
PLoS ONE, Vol 10, Iss 1, p e0116577 (2015)
The development of neutralizing anti-factor VIII (FVIII) antibodies complicates the treatment of many hemophilia A patients. The C-terminal C2 domain is a particularly antigenic FVIII region. A crystal structure of recombinant FVIII-C2 bound to an Fa
Externí odkaz:
https://doaj.org/article/9f01ce1acfea4daca262cfb00998c208
Autor:
Bryan R. Moser, Bruce S. Dien, Denise M. Seliskar, Arthur R. Thompson, Loren B. Iten, John L. Gallagher, Steven F. Vaughn
Publikováno v:
Biomass and Bioenergy. 59:300-305
Seashore mallow ( Kosteletzkya pentacarpos (L.) Ledebour) is a perennial halophyte producing multiple, harvestable stems per year which were examined for several bioabsorbent applications. Larger, debarked stems were milled and separated into three f
Publikováno v:
Industrial Crops and Products. 51:437-443
Biochar is the solid, carbon-rich product resulting from the pyrolysis of biomass in the absence of oxygen. We are examining biochars for several horticultural applications, including as a replacement for peat moss in soilless substrates used in the
Autor:
Arthur R. Thompson, H. Marijke van den Berg, Maurizio Margaglione, Connie H. Miller, Samantha C. Gouw, Jorien Boekhorst, Saskia le Cessie, Johanna G. van der Bom, Jan Astermark, Waander L. van Heerde, Johannes Oldenburg, Philip G. de Groot
Publikováno v:
Blood, 119, 12, pp. 2922-34
Blood, 119, 2922-34
Blood, 119(12), 2922-2934
Blood, 119, 2922-34
Blood, 119(12), 2922-2934
This systematic review was designed to provide more precise effect estimates of inhibitor development for the various types of F8 gene mutations in patients with severe hemophilia A. The primary outcome was inhibitor development and the secondary out
Autor:
Pedro Paz, Fred Aswad, Kathleen P. Pratt, Dana C. Matthews, Ruth A. Ettinger, Eddie A. James, Arthur R. Thompson, Devi Gunasekera
Publikováno v:
Blood. 128(16)
Factor VIII (FVIII)-neutralizing antibodies ("inhibitors") are a serious problem in hemophilia A (HA). The aim of this study was to characterize HLA-restricted T-cell responses from a severe HA subject with a persistent inhibitor and from 2 previousl
Publikováno v:
Blood. 114:1423-1428
The development of neutralizing antibodies (inhibitors) after factor VIII (FVIII) infusions is a serious complication that affects approximately one-quarter of hemophilia A patients who have access to replacement therapy. To investigate the different
Autor:
V. Tsourea, Kathleen P. Pratt, Arthur R. Thompson, N. Sirocova, S. M. Nakaya, N. Barbacar, M. Vicol
Publikováno v:
Haemophilia. 15:942-951
Haemophilia A (HA) is a bleeding disorder caused by mutations within the X-linked F8 gene. A series of 42 unrelated Moldovan patients with HA had their disease-causative mutation determined to provide clinically valuable genotyping information for a
Autor:
Arthur R. Thompson, Kathleen P. Pratt
Publikováno v:
Clinical Reviews in Allergy & Immunology. 37:80-95
Adequate hemostasis is achieved for many hemophilia A patients by infusion of plasma-derived or recombinant factor VIII (FVIII), but unfortunately, a significant subset of patients develop an immune response in which anti-FVIII antibodies, referred t
Publikováno v:
Journal of Thrombosis and Haemostasis. 5:2399-2407
Summary. Background: Antibodies that neutralize factor (F) VIII activity, clinically referred to as ‘inhibitors’, complicate the treatment of hemophilia A patients; current tolerance and bypass strategies are extremely costly and sometimes ineffe